BioIVT to Highlight its Drug-Drug Interaction and ADME Research Expertise at the SOT Annual Meeting and ToxExpo
BioIVT, a leading provider of biospecimens, research models, and services for drug and diagnostic development, today announced its scientific contributions to the 2023 Society of Toxicology (SOT) 62nd Annual Meeting and ToxExpo. This year’s conference will be held from March 19-23 at the Nashville Music City Center in Nashville, TN.
“We look forward to catching up with our research colleagues at the SOT Annual Meeting and discussing recent scientific advances,” said Dr. Christopher Black, BioIVT Senior Vice President, ADME-Tox. “Our goal at BioIVT is to be the trusted partner for in vitro research, whether we are providing hepatic products for internal programs or designing and implementing research in our labs. Therefore, it is important for us to meet clients in person to discuss their research goals. We are also excited to have this opportunity to discuss how our recent acquisitions of XenoTech and Cypex have enabled us to expand our capabilities further to meet their needs.”
Dr. Brian Ogilvie, BioIVT VP of Scientific Consulting, will discuss “In Vitro Drug-Drug Interaction (DDI) and ADME Considerations for Toxicologists” on March 22 at 9:00 am.
“In vitro ADME DDI investigations are critical for framing downstream decision-making,” explained Dr. Ogilvie. “During this presentation, I will provide strategies to de-risk each stage of the R&D pipeline, with particular focus on regulatory drivers, investigatory objectives, and practical concerns that are relevant to toxicologists. I’ll cover study design, data interpretation, and red flags to look for in in vitro DDI study reports.”
BioIVT will also co-present a research poster entitled “Prediction of Clinically Relevant Botanical-Drug Clearance Interactions for Boswellia serrata Extract using Sandwich-Cultured Human Hepatocytes,” which summarizes its collaboration with the Procter & Gamble Company (P&G). This work, which was funded by P&G, examines the impact of botanical dietary supplements on drug efficacy and safety.
BioIVT’s sandwich cultured human hepatocyte (SCHH) system with TRANSPORTER CERTIFIED hepatocytes was used to investigate botanical-drug interactions and the potential effects of botanical dietary supplements on CYP450 enzymes.
Products and Services
BioIVT’s research support includes consulting services to help clients design ADME and investigational new drug (IND) strategies, extensive laboratory and data analysis capabilities, and the ability to produce submission-ready reports. The company also offers a comprehensive portfolio of extensively characterized cells, and dependable product availability via its secure supply chain.
BioIVT experts will be available to answer questions about the company’s hepatic product portfolio and ADME-Tox research services at booth #1103. Meetings can also be scheduled in advance of the SOT Annual Meeting at https://info.bioivt.com/sot-2023-exhibit.
Further information about this conference is available at https://www.toxicology.org/events/am/AM2023/index.asp.
BioIVT is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. And as the premier supplier of hepatic products, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE® For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.